Thrombolysis with 0.6 mg/kg intravenous alteplase for acute stroke in routine clinical practice: the outline of Japan post-Marketing Alteplase Registry Study (J-MARS)

Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients — A preliminary study

“…However, J-MARS showed that the frequency of favorable outcome at 3 months in patients between 18 and 80 years with a baseline NIHSS score b25 was 39%, which suggested that 0.6 mg/kg intravenous alteplase should be safe and effective. [25] In J-MARS, edaravone was used in 74.6% of 7492 patients (unpublished), but it was not known when edaravone was administered before and after t-PA infusion. Furthermore, J-ACT II showed that the frequency of early recanalization of the occluded MCA within 6 h after t-PA infusion was about 50% and induced a favorable clinical outcome, compatible to that previously reported with the 0.9 mg/kg dose [26].…”

Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke

“…The Japan post-Marketing Alteplase Registration Study (J-MARS) assessed the safety and efficacy of 0.6 mg/kg rtPA in routine clinical practice in Japan. 12 The study enrolled 7492 patients and the rates of symptomatic ICH, death and three-month favorable outcome were 3.5%, 13.1% and 33.1%, respectively. The lower rate of symptomatic ICH in J-MARS may be explained by the lower dose of rtPA used.…”

Recanalization Therapy for Internal Carotid Artery Occlusion Presenting as Acute Ischemic Stroke

“…Its use might be based on recent Japanese studies 26,27 and Interventional Management of Stroke I and II trials. 18,19 The ENhanced Control of Hypertension ANd Thrombolysis in strokE Disease trial may solve the controversy related to tPA dose, but the aim of this trial is to compare 2 different doses of tPA in patients receiving IVT alone regardless of occlusion status.…”